
Images are representative. Products are lyophilised research peptides in sterile vials. COA shown above when available for the current batch.
Cagrilintide
Long-acting lipidated amylin analog for weight management and metabolic research.
Cagrilintide (AM833) is a long-acting lipidated amylin analog acting as a dual amylin and calcitonin receptor agonist, with a half-life of approximately 7.5 days that supports once-weekly dosing. Phase 3 research has demonstrated significant weight reduction as monotherapy and superior efficacy in combination with semaglutide (CagriSema), reaching up to 22.7% weight loss in trial participants. Each vial is lyophilised under nitrogen, HPLC-verified at ≥99% purity, and ships with a full Certificate of Analysis.
For research calculation only. Not dosing guidance. U-100 = 100 units per ml.